Suppr超能文献

用编码血凝素(HA)或核蛋白(NP)基因的重组改良安卡拉痘苗病毒(rMVA)构建体进行免疫接种,可保护小马免受马流感病毒攻击。

Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge.

作者信息

Breathnach C C, Clark H J, Clark R C, Olsen C W, Townsend H G G, Lunn D P

机构信息

Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA.

出版信息

Vaccine. 2006 Feb 20;24(8):1180-90. doi: 10.1016/j.vaccine.2005.08.091. Epub 2005 Sep 12.

Abstract

Two novel recombinant strains of modified vaccinia Ankara (rMVA) for the vaccination of horses against equine influenza virus were developed, and preliminary evidence of their immunogenicity in ponies was demonstrated [Breathnach CC, Rudersdorf R, Lunn DP. Use of recombinant modified vaccinia Ankara vectors for equine influenza vaccination. Vet Immunol Immunopathol 2004:98;127-36]. The present study assessed the protective efficacy of these rMVA strains in ponies, examined the advantage of combining rMVA vaccination with a DNA priming dose, and investigated the protection resulting from equine influenza nucleoprotein (NP) versus haemagglutinin (HA) vaccination. Twenty yearling ponies, seronegative for equine influenza virus, were divided into four groups of five. Group 1 and Group 2 ponies were vaccinated using a DNA prime-rMVA boost vaccination regimen, with HA- or NP-expressing vectors, respectively. Group 3 ponies were vaccinated with rMVA-HA only. Group 4 ponies served as unvaccinated controls. Vaccines were administered on days 0, 42 and 70, and all ponies were challenge infected with influenza virus on day 100. Antigen-specific antibody and cellular immune responses to each vaccination regimen were monitored throughout the experiment. Both groups of HA-vaccinated ponies were significantly protected from clinical disease following challenge infection, demonstrating the efficacy of rMVA vaccination with or without a DNA prime. NP-vaccination provided more limited protection from clinical disease. The protective post-vaccinal immune responses were characterized by antigen-specific IgGa, IgGb and IgA antibodies which were induced both in serum and in nasal secretions. Virus-specific lymphoproliferative and IFN-gamma mRNA responses were also elicited by each vaccination regimen. These data demonstrate that vaccination of horses with rMVA alone, or as part of a prime-boost regimen, is an effective means of inducing protective immunity to influenza virus infection, and also indicate that NP-specific immune responses can contribute to protection of horses.

摘要

开发了两种用于马匹预防马流感病毒的新型重组安卡拉痘苗病毒(rMVA)毒株,并在小马身上证明了它们免疫原性的初步证据[Breathnach CC, Rudersdorf R, Lunn DP. 使用重组安卡拉痘苗病毒载体进行马流感疫苗接种。兽医免疫学与免疫病理学2004:98;127 - 36]。本研究评估了这些rMVA毒株在小马中的保护效果,研究了将rMVA疫苗接种与DNA初免剂量相结合的优势,并探讨了接种马流感核蛋白(NP)与血凝素(HA)疫苗所产生的保护作用。20匹对马流感病毒血清学阴性的一岁小马被分为四组,每组5匹。第1组和第2组小马采用DNA初免 - rMVA加强疫苗接种方案,分别使用表达HA或NP的载体进行接种。第3组小马仅接种rMVA - HA。第4组小马作为未接种疫苗的对照。疫苗分别在第0、42和70天接种,所有小马在第100天接受流感病毒攻击感染。在整个实验过程中监测了每种疫苗接种方案的抗原特异性抗体和细胞免疫反应。两组接种HA疫苗的小马在攻击感染后均显著免受临床疾病的侵害,证明了无论有无DNA初免,rMVA疫苗接种均有效。接种NP疫苗对临床疾病的保护作用较为有限。接种疫苗后的保护性免疫反应的特征是血清和鼻分泌物中均诱导产生了抗原特异性IgGa、IgGb和IgA抗体。每种疫苗接种方案还引发了病毒特异性淋巴细胞增殖反应和IFN - γ mRNA反应。这些数据表明,单独使用rMVA对马匹进行疫苗接种,或作为初免 - 加强方案的一部分,是诱导对流感病毒感染产生保护性免疫的有效手段,并且还表明NP特异性免疫反应有助于保护马匹。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验